Amplia Therapeutics (ASX:ATX) Short Interest


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.14
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:ATX vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Amplia Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Short Interest falls into.


ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price